密骨片对PMOP的骨密度、MMP-2及骨代谢指标的影响

Effects of Migu tablet on bone mineral density,serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis

目的：观察密骨片（Migutablet）治疗绝经后骨质疏松症的血清基质金属蛋白酶-2（MMP-2）水平及骨密度（BMD）、骨代谢指标的变化。方法：将年龄55～62岁的192名自然绝经的妇女进行骨密度测定，骨质疏松妇女160例随机分为：密骨片（MG）组68例，仙灵骨葆（XLGB）组50例，钙剂组42例；绝经后正常妇女32例作为正常组。各组均于用药前后12，24周，采用酶联免疫吸附试验（ELISA）测定的血清MMP-2水平、骨碱性磷酸酶（sBAP）、骨钙素（sOC）、I型胶原交联C端肽（sCTx）和尿Ⅰ型胶原交联N端肽（uNTx），用双能X线吸收法（DEXA）测定腰椎正位，股骨颈，Ward’s三角和大粗隆的骨密度（BMD）。结果：经治疗后，密骨片组和仙灵骨葆组骨密度均有不同程度的提高，而钙剂组和正常组骨密度均下降；密骨片组和仙灵骨葆组的sBAP，sOC均有明显升高，而MMP-2，sCTx，uNTx明显下降，钙剂组和正常组变化不明显。结论：密骨片治疗绝经后骨质疏松症疗效显著，与仙灵骨葆相仿。单纯服用钙剂不能治疗绝经后骨质疏松症，且继续骨流失。

Objective： To study the effects of Migu tablet（MG） on bone mineral density （BMD）, serum matrix metaUoproteinase-2 （MMP-2） and bone metabolic markers in Chinese postmenopausal women. Method： According to the criteria of osteoporosis, 192 Chinese postmenopausal female of the aged 55-62 were randomized into 4 groups, such as the normal, MG group, XLGB group and Leli group. The serum MMP-2, bone alkaline phosphates （sBAP）, osteocalcin （sOC）, bone cross-linked C-telopeptides of type Ⅰ collagen （sCTx） and urine bone cross-linked N-telopeptides of type Ⅰ collagen （uNTx） were measured using ELISA. BMD were measured using dual energy X-ray absorptiometry before and after medication at 12 and 24 weeks. Result： After treatment, the values of BMD were significantly higher in MG and XLGB groups separately, otherwise lower in Leli and normal control groups. At the same time, serum MMP-2, sCTx, uNTx/Cr concentrations were significantly lower and sBAP, sOC concentrations were higher, but the concentrations in Leli and normal control groups were basically same to the value of before treatment. Conclusion： The effects of MG tablet to treat the PMO were notable, just same to XLGB. But calcium tabht cannot play a role in the treatment of osteoporosis and do not prevent the loss of bone.